Formulation & Aseptic Fill-Finish (Grade A Isolators)

Design → GMP, without detours. Where most shops stop at fermentation, we finish the job: high-concentration protein formulation that behaves in the syringe, vesicle and phage bulk that survives without 0.22 µm filtration, and Grade A isolator fills (vials / prefilled syringes / cartridges) that pass inspection the first time.

Executive overview

Filling a biologic is not the end of a process—it is the moment the whole programme either coheres or comes apart. Proteins at 150 mg/mL look fine until viscosity doubles the injection force. Vesicles remain “intact” by one assay and silently aggregate in transit. Phage bulk cannot be sterilised by filtration, so asepsis must be designed into every junction and hold. Container–closure picks up the slack (or doesn’t). And stability either reflects the route and logistics—or the label promise becomes an argument.

Mika Biologics runs formulation and fill-finish as a single, disciplined thread: QTPP → CQAs → CPPs set on day one; formulation design space that protects mechanism and logistics; fill in Grade A isolators with Grade B background; deterministic container closure integrity (CCI); and ICH stability that reveals movement without inventing failure. We specialise in microbial-first modalities: soluble and high-viscosity proteins (E. coli, Pichia), enzymes and bacteriocins, phage and phage-derived enzymes, VLPs/OMVs/EVs, and engineered probiotics where asepsis and presentation still matter.

Interlock this service with Analytical & QC for Microbial Biologics (methods/COAs), Process Characterization, PPQ & CPV (hold-times, ranges), Yeast & Fungal Expression Systems, Advanced Yeast Glycoengineering, Exosomes & OMVs, and Engineered Probiotics (LBP) GMP.

What we deliver

• Formulation architecture for proteins, particles, and live/viral products: buffers, excipients, cryo/lyo-protectants, surfactant policy, oxygen and light budgets, and human-factors constraints (injection force, reconstitution time).
• Viscosity management for high-concentration proteins: pH and ionic strength tuning, arginine/salt systems, self-association control, and autoinjector feasibility mapping (needle gauge vs force vs time).
• Particle/VLP/EV/phage design: gentle buffers, divalent cation logic, ionic strength windows, and shear-calm unit operations that preserve morphology and titre.
• Lyophilisation: cycle development (Tg′/Tc, controlled nucleation, annealing), cake mechanics and residual moisture windows, reconstitution kinetics, and Pirani–capacitance convergence for objective endpoints.
• Aseptic fill-finish in Grade A isolators: vials, prefilled syringes (PFS), and cartridges; closed-path bulk management; time-in-solution and temperature limits; nitrogen overlays and headspace controls.
• Container systems: type I glass and COP/COC polymers; stoppers/plungers with silicone policy; baked-on vs sprayed silicone for glide-force stability; needle/tungsten risk management.
• Container–Closure Integrity (CCI): deterministic methods (helium leak, vacuum decay, HVLD, headspace analysis) with acceptance linked to route and shelf-life; dye ingress used only as supportive evidence.
• ICH stability: phase-appropriate real-time and accelerated arms with stability-indicating methods aligned to mechanism (e.g., ADCC, PFU, particle size, CFU).
• Documentation: batch records (eBR), media fills, EM trending to EU Annex 1 (2022), and inspection-ready reports.

Programme design: QTPP → CQAs → CPPs

We begin with a single sheet that anchors the entire effort:

• QTPP (examples): route (IV/SC/oral/local), dose and volume, DS/DP presentation (vial, PFS, cartridge), storage (2–8 °C vs lyo ambient), in-use handling, injection force target, reconstitution ≤ X min, shelf-life Y–Z months.
• CQAs: identity and potency (mechanism-true), aggregate fraction (SEC-MALS), subvisible particulate counts, viscosity at defined shear rates, CCI pass, sterility/bioburden, endotoxin (route-appropriate), particle size and count (NTA/DLS/EM for VLP/EV), PFU (phage), CFU/payload (LBP), reconstitution time, appearance, pH/osmolality.
• CPPs: buffer pH and ionic strength, excipient identity/level, antioxidant/light/oxygen controls, shear exposure (pumps/filters/needles), time-in-solution at ambient/cold, fill temperature, nitrogen headspace, stopper siliconisation, lyo shelf temperatures and pressure profiles, hold-times at each node.

Everything else follows from this sheet, including sampling plans and the CCI method stack.

Formulation menus by modality

High-concentration proteins (enzymes, antibodies, Fc-fusions)

• Buffers: histidine or citrate/phosphate depending on pH; ionic strength tuned to minimise self-association without provoking opalescence.
• Viscosity handling:
  • Adjust pH away from pI to reduce attractive interactions.
  • Arginine (and related amino acids) or NaCl as structure-breaking co-solutes to reduce viscosity without compromising stability.
  • Map rheology under relevant shear and extensional regimes; compute injection force vs needle gauge (27–29 G typical) and time.
  • Explore co-formulations (e.g., hyaluronidase) only where the claim supports it.
• Surfactants: define polysorbate policy (PS20/PS80) vs alternatives; quantify peroxide and fatty-acid risks; include antioxidant/light control if necessary.
• Aggregation control: temperature ramps, low-shear mixing, avoid cavitation; filter and transfer materials selected by adsorption screens.

VLPs, OMVs, exosomes, and other particles

• Buffers: physiological ionic strength with divalent cation logic to stabilise membranes/capsids; avoid detergents unless demonstrably required.
• Shear management: peristaltic/diaphragm pumps and wide-bore needles; no dead-leg manifolds; low dP filtration policies; hold-time boundaries proven.
• Osmotic shocks: explicitly ruled out with pre- and post-fill checks.
• Endotoxin: a process and acceptance story that fits route and particle class.

Bacteriophages & phage-derived enzymes

• Phage DP: gentle ionic balance, divalent cations as needed for tails; surfactants used sparingly; no 0.22 µm sterilising filtration—aseptic closed processing instead.
• Lytic enzymes: classical protein logic plus endotoxin control and activity assays that read true under formulation conditions.

Engineered probiotics (LBP)

• Suspensions: isotonic, pH-appropriate, refrigerated with tight time-in-solution; bioburden policies near parenteral where route demands.
• Lyo powders / capsules: moisture and oxygen budgets; enteric coatings (HPMC-AS / CAP / methacrylate) tuned to site of action; microencapsulation where colon targeting is vital.

Lyophilisation that behaves in clinic

We develop cycles that protect potency and logistics:

1. Thermal characterisation: Tg′/Tc and eutectic mapping by DSC and microscopy; identify annealing benefits for bulking agents (e.g., mannitol crystallisation).
2. Controlled nucleation (when indicated) to tighten cake consistency and reduce reconstitution variance.
3. Primary drying below Tc/Tg′ with product thermocouples where appropriate; Pirani vs capacitance convergence for objective endpoints.
4. Secondary drying to residual moisture windows that balance stability with reconstitution speed.
5. Cake analytics: specific surface area, moisture/water activity, mechanical integrity, reconstitution time and foaming profile.
6. For particles and phage: cryo/lyo-protectant cocktails (trehalose/sucrose + amino acids) and oxygen/light controls to prevent envelope/capsid damage.

Presentations and human-factors

• Vials: type I borosilicate or polymer (COP/COC) where E&L or breakage risk demands; nitrogen headspace for oxygen-sensitive products; flip-off seals consistent with storage.
• Prefilled syringes (PFS): baked-on vs sprayed silicone policy; glide-force and break-loose characterisation over shelf-life; tungsten management for staked needles; needle gauge tuned to viscosity/injection time; autoinjector compatibility files (force vs time curves).
• Cartridges: pen/auto-injector readiness, CCI and delamination risk controlled; polymer options where glass risk is high.
• Accessories: filters/needles/transfer devices validated for adsorption and particle generation.

Aseptic fill-finish in Grade A isolators

• Environment: Grade A isolators in Grade B background; EM (air and personnel) aligned to EU Annex 1 (2022); media fills at the worst-case configuration and duration.
• Product contact: single-use fluid paths; validated cleaning/SIP where stainless is used.
• Operations:
  • Closed-system bulk from compounding to fill bowl.
  • Time-in-solution and temperature limits for every batch, with alarms on the HMI.
  • Nitrogen overlays and controlled headspace for oxidation-sensitive formulations.
  • IPC at the line: in-process weight checks, temperature at fill, periodic particle checks for sensitive modalities.
• Sterile filtration: where compatible (proteins, many solutions), we qualify 0.22 µm filters (adsorption, throughput). Where incompatible (phage/EV/OMV), we validate closed aseptic processing with bioburden controls and sterility at release.

Container–Closure Integrity (CCI)

We prioritise deterministic methods:

• Helium leak (MS) for high-sensitivity verification;
• Vacuum decay and HVLD as appropriate to presentation;
• Headspace gas analysis (oxygen) for oxygen-sensitive goods and as an in-line monitor;
• Dye ingress only as supportive testing.

Acceptance criteria link to the route, shelf-life, and transport simulation. For PFS/cartridges we tie CCI and glide-force to silicone policy and stopper/plunger choices.

ICH stability that answers the real question

• Design: long-term at label storage (e.g., 2–8 °C; ambient for lyo) and accelerated/excursion arms that mirror likely transport and in-use risks.
• Stability-indicating methods:
  • Proteins: potency (e.g., enzymatic or ADCC), aggregates (SEC-MALS), charge variants (icIEF), particles (subvisible), viscosity.
  • Particles: NTA/DLS/EM convergence, potency, endotoxin drift, appearance.
  • Phage: PFU retention, residual DNA drift, appearance.
  • LBPs: CFU decay, payload activity, package oxygen/moisture creep, kill-switch responsiveness.
• Reconstitution (where relevant): time to clarity and potency retention post-reconstitution under in-use windows.
• Label writing: the stability report directly supports label storage, in-use, and transport statements; no wishful claims.

In-process controls (IPCs) that keep batches inside the rails

• Compounding: pH and conductivity after each addition; osmolality where relevant; visual clarity/opalescence checks; bioburden (pre-filtration, where applicable).
• Filtration: filter integrity (pre/post), differential pressure, hold-up loss; adsorption check for first-article lots.
• Fill: fill weight, temperature, time-in-solution clocks, headspace oxygen (for sensitive products).
• Post-fill: crimp quality, visual inspection, sample retain policy, transit simulation (shake/temperature) as part of PQ.

Case-style patterns

• 150 mg/mL Pichia Fc-fusion for SC: viscosity reduced by pH shift + arginine; PS80 policy with peroxide control; autoinjector profile met (29 G, ≤ 10 s). CCI by vacuum decay and helium leak; 24-month lyo shelf-life with ≤ 1.5% aggregates.
• Phage cocktail, non-filterable: closed isolator fill; nitrogen overlay; ionic balance to protect tails; PFU loss ≤ 0.2 log over Month 6; sterility/bioburden consistently pass.
• OMV vaccine: SEC-polished bulk; low-shear peristaltic fill; NTA/DLS/EM convergence locked; HVLD CCI; 2–8 °C logistics with validated agitation tolerance.
• LBP capsules: lyo protectants + enteric coating; residual moisture 1.8%; package O₂ ≤ 1%; CFU loss < 0.5 log/year at ambient; colon-release time verified in USP apparatus.

Documentation and validation spine

• MBR/eBR and compounding worksheets with material balances.
• Isolator PQ: media fills, airflow, decon cycles; EM limits and actions.
• Filter/line validation: adsorption, throughput, integrity; worst-case lots captured.
• Lyo PQ: cycle reproducibility; Pirani–capacitance endpoint agreement windows.
• CCI validation: method capability (detection limits), defect library, sample sizes.
• Stability protocol & report: aligned to label claims and pharmacopoeia.
• Change control and comparability: clear lanes for formulation tweaks, container changes, and site transfers—assay panels and acceptance bands pre-agreed.

Onboarding in 30 days

• Day 10: QTPP → CQA → CPP map; risk register; sampling plan.
• Day 20: Draft composition ranges; viscosity/injection force model; preliminary lyo targets (if relevant); proposed CCI stack.
• Day 30: Draft control strategy; isolator and CCI validation outlines; stability design; first golden-batch traces.

Inter-page guidance

• Analytical & QC for Microbial Biologics: method menus, rFC/LAL, particle analytics, and sample COAs.
• Process Characterization, PPQ & CPV: scale-down, ranges, and CPV dashboards for hold-times and lyo signatures.
• Advanced Yeast Glycoengineering (Pichia): when glycan state drives viscosity and potency.
• Exosomes & OMVs and Phage Therapeutics & Enzymes: particle/phage-specific formulation nuances.
• Engineered Probiotics (LBP): capsule and sachet architectures and consortia blending.

FAQ

Do you always sterilise through 0.22 µm filters?
No. For non-filterable products (phage, OMVs/EVs), we execute closed aseptic processing in Grade A isolators with validated bioburden control and sterility testing at release.

How do you keep high-concentration proteins injectable?
We map viscosity vs pH/ionic strength, deploy arginine/salt systems where justified, limit self-association, and model injection force vs time and needle gauge. Formulation is locked to an autoinjector feasibility envelope.

What CCI methods do you use?
Primarily helium leak, vacuum decay, HVLD, and headspace oxygen. Dye ingress is supportive, not primary. Acceptance ties to route and shelf-life.

How is lyophilisation developed?
We characterise Tg′/Tc, use controlled nucleation when helpful, set primary/secondary drying with Pirani–capacitance agreement, and specify residual moisture windows that balance stability and reconstitution.

Can you fill cartridges as well as vials and PFS?
Yes. Cartridges are standard; we manage glide-force, CCI, and E&L, and produce autoinjector compatibility data.

How do you manage oxygen/light-sensitive products?
Nitrogen overlays, headspace monitoring, light-blocking packaging, and antioxidant/excipient policies. Headspace oxygen becomes a CCI and ageing sentinel.

What stability claims are realistic?
We design to the route and logistics. Proteins typically carry 2–8 °C liquid or lyo ambient labels; particles favour 2–8 °C; LBPs can achieve ambient lyo with moisture/oxygen budgets. The data, not optimism, sets the claim.

Can you support parenteral and oral products in the same facility?
Yes—through segregated suites, material/people flows, and validated changeover. Aseptic standards remain constant.